Semaglutide 20mg is a synthetic 31-amino-acid polypeptide engineered as a glucagon-like peptide-1 (GLP-1) receptor agonist, supplied by Echo Peptides strictly for in-vitro and preclinical laboratory research. As a reference GLP-1 analog, it serves as a stable molecular tool for investigators probing incretin receptor signaling in cell-culture and other controlled experimental systems.

Its structure carries deliberate modifications that distinguish it from native GLP-1: an aminoisobutyric acid (Aib) residue at position 8 confers resistance to DPP-4 cleavage, an arginine substitution at position 34 refines receptor selectivity, and a C18 fatty diacid chain enables albumin binding. Together these features extend the peptide's stability in research models, making it a durable reference compound for studying receptor-mediated pathways over prolonged in-vitro time courses.

Key research areas

  • Glucose-dependent insulin secretion mechanisms in cell-based models
  • Glucagon suppression pathways
  • Gastric emptying and appetite regulation research models
  • Glycemic control and broader metabolic research

Specifications

  • Quantity: 20mg, lyophilized
  • Form: Freeze-dried powder in a sterile vial
  • Composition: Synthetic 31-amino-acid polypeptide; GLP-1 receptor agonist
  • Structural modifications: Aib at position 8 (DPP-4 resistance), Arg at position 34, C18 fatty diacid chain for albumin binding (lipidated for extended half-life in laboratory settings)
  • Purity: High purity
  • Identity and purity: Third-party tested; a Certificate of Analysis is available

Strictly for in-vitro laboratory research use only. Not for human consumption, veterinary, diagnostic, or therapeutic applications.